Table 1 Characteristics of the included 8 randomized controlled trials.
Study | Number | Dosage | Time | Type of operation | Type of anesthesia | Injection time |
|---|---|---|---|---|---|---|
Bondok23 | Mg: 30 | 500 mg (10 ml) | 1, 2, 6, 8, 12, 18, 24 h | Arthroscopic knee meniscectomy | General | At the end of the surgery |
Placebo: 30 | (10 ml) | |||||
Elshamouby24 | Mg: 27 | 1000 mg (20 ml) | 1, 2, 4, 6, 8, 12, 24 h | Arthroscopic knee meniscectomy | General | At the end of the surgery |
Placebo: 27 | (20 ml) | |||||
B: 27 | 0.25% (20 ml) | |||||
Mg plus B: 27 | 1000 mg plus 0.25% (20 ml) | |||||
Farouk25 | Mg plus B: 20 | 150 mg plus 0.25% (20 ml) | 1, 2, 24 h | Arthroscopic knee meniscectomy | General | At the end of the surgery |
B: 20 | 0.25% (20 ml) | |||||
Suhrita30 | Mg plus B: 30 | 500 mg plus 0.25% (20 ml) | 1, 2, 6, 10, 14, 18 h | Arthroscopic knee meniscectomy and ligament repair | General | At the end of the surgery |
B: 30 | 0.25% (20 ml) | |||||
Koltka26 | Mg: 30 | 500 mg (20 ml) | 1, 2, 4, 12, 24, 48 h | Arthroscopic knee meniscectomy | General | At the end of the surgery |
Placebo: 30 | (20 ml) | |||||
LB: 30 | 0.5% (20 ml) | |||||
Radwan27 | Mg: 20 | 800 mg (20 ml) | 1, 2, 4, 6, 12, 24 h | Arthroscopic knee meniscectomy | General | At the end of the surgery |
B: 20 | 0.5% (20 ml) | |||||
Saritas28 | Mg: 30 | 100 mg/ml (10 ml) | 1, 2, 6, 8, 12, 18, 24 h | Arthroscopic rotator cuff repair | General | At the end of the surgery |
Placebo: 30 | (10 ml) | |||||
Abdulatif29 | Mg: 28 | 1000 mg (20 ml) | 2, 4, 6, 12, 24 h | Arthroscopic ACL reconstruction | General | At the end of the surgery |
Placebo: 27 | (20 ml) |
